Ann: Trading Policy, page-12

So what do they need to do Akki for PK/ PD to be ok? I assume they would need to identify the lead candidate fpp for a given cell, then go ahead and develop the data for that fpp in that given situation? I assume one problem with the large libraries is each individual fpp would need its own PK/PD data?

From a definition of PK PD in case it is of interest to anyone "The Pharmacokinetics (PK) is the study of the way body handles the drug by absorption, distribution, metabolism
and excretion. The Pharmacodynamics (PD) would be the body’s pharmacological response to a drug. Assess-
ment of PK/PD data variability population along with safety or efficacy data in early phases of clinical trials is an
important aspect of clinical data analysis. The derived PK/PD dataset for analysis may contain any PK data along
with safety or efficacy data"